Table 3. Establishment of PDX from soft tissue and bone tumors.

PDX: patient-derived xanograft, listed from the higher number of samples obtained and rate of established PDX.

	Diagnosis	Biological potential	Number of cases	PDX
1	Myxofibrosarcoma (MFS)	malignant	１2	6 （50.0%）
1	Myxoid liposarcoma	malignant	12	4 （33.3％）
3	Undifferentiated pleomorphic sarcoma (UPS)	malignant	10	5 （50.0％）
4	Chondrosarcoma	intermediate	10	0 （0％）
4	Giant cell tumor of bone (GCTB)	intermediate	9	0 （0％）
6	Dedifferentiated liposarcoma (DDLP)	malignant	7	4 （57.1％）
7	Ewing sarcoma	malignant	6	2 （33.3%)
8	Osteosarcoma	malignant	5	3 （60.0%)
8	Schwannoma	benign	5	0 （0％）
10	Dermatofibrosarcoma protuberans (DFSP)	intermediate	４	1 （25.0%）